OABI

OMNIAB, INC.

Company Overview

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

SectorHealthcare
IndustryBiotechnology
Market Cap$627.7M
Employees89
CEOMatthew W. Foehr

Valuation

Current Price$4.33
Fair Value?$000.00
Valuation?No valuation
Hist. PE ?N/A
EPS (TTM) ?-0.34
Forward EPS Growth ?
Historical Growth ?-5.18%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price

EPS

Revenue

Equity

Pro

Available on the Pro plan

Free Cash Flow

Pro

Available on the Pro plan

Long Term Debt

Pro

Available on the Pro plan

Net Profit

Pro

Available on the Pro plan

Shares Outstanding

Pro

Available on the Pro plan

Last updated: 9/5/2026, 6:38:55 PM